FDA
-
-
-
-
-
-
-
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
-
-
-
-
-
-
-
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
-
-
-
-
-
-
-
TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial
-
-
-
-
-
-
-
TransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic Cancer
-
-
-
-
-
-
-
TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors
-
-
-
-
-
-
-
TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update
-
-
-
-
-
-
-
TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

